AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19016569
Drug: 4-mL Vacutainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mL Vacutainer connected to the needle (Group 2)
Trial: 12452872
Drug: UVA irradiation
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA irradiation (cumulative doses of 96 J cm‐2 for skin type II and 126 J cm‐2 for skin type III)
Trial: 8129608
Drug: Preoperative, noninvasive:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative, noninvasive: The redox tolerance test (RTT) measuring changes in arterial ketone body ratio in response to 75 g of oral glucose loading.
Trial: 9032569
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol alone
Trial: 31645305
Drug: Blood components
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood components therapy
Trial: 29019364
Drug: Blueberry treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry treatment (BB; 300 g of blueberry)
Trial: 29019364
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (C; 300 mL of water with sugar)
Trial: 29019364
Drug: Blueberry treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry treatment with smoking (BS; 300 g of blueberry + smoking)
Trial: 29019364
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment with smoking (CS; 300 mL of water with sugar + smoking)
Trial: 29019364
Drug: Smoking treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking treatment (S)
Trial: 19826306
Drug: Carbohydrate-electrolyte beverage
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte beverage (6% or 60 g L(‐1))
Trial: 17082474
Drug: Granulocyte-colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony-stimulating factor (G-CSF) 10 microg/kg for 5 days
Trial: 11297210
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (10(6) KIU after induction of anesthesia and 10(6) KIU in pump prime)
Trial: 9226484
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of water soluble fibre (guar gum) daily for 14 months
Trial: 2888185
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg HOE 760
Trial: 28084834
Drug: Interactive Behavioral
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Behavioral Modification Therapy
Trial: 27480314
Drug: Protocolized sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized sedation with daily sedation interruption
Trial: 25527842
Drug: Corticosteroid and
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid and local anaesthetic injections administered by a physiotherapist
Trial: 25527842
Drug: Corticosteroid and
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid and local anaesthetic injections administered by an orthopaedic surgeon
Trial: 22898679
Drug: Imatinib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib with chemotherapy (good-risk group)
Trial: 22898679
Drug: No imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No imatinib with chemotherapy (good-risk group)
Trial: 22898679
Drug: Imatinib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib with chemotherapy (as-treated analysis, good-risk group)
Trial: 22898679
Drug: No imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No imatinib with chemotherapy (as-treated analysis, good-risk group)
Trial: 22898679
Drug: Imatinib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib with chemotherapy (poor-risk group)
Trial: 20384990
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to clinical practice guidelines (CPGs)
Trial: 20384990
Drug: Non-treatment or
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment or treatment not according to CPGs
Trial: 18362489
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg daily for 4 weeks
Trial: 12163992
Drug: Concomitant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemoradiation with cisplatin 40 mg/m2 weekly for 6 courses and HDR brachytherapy (7 Gy in point A per fraction, total dose 35 Gy)
Trial: 7486115
Drug: Propofol blood
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol blood concentration 1 microgram/mL
Trial: 7486115
Drug: Propofol blood
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol blood concentration 2 micrograms/mL
Trial: 6769773
Drug: Oral thioctic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral thioctic acid for 21 days
Trial: 6769773
Drug: Intravenous thioctic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thioctic acid for 21 days
Trial: 25403264
Drug: Pomalidomide plus
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide plus low-dose dexamethasone (POM+LoDEX)
Trial: 26149712
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HiDEX)
Trial: 23095185
Drug: DHA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA group (200 mg/day DHA)
Trial: 16436239
Drug: Méniètt device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Méniètt device (local overpressure treatment)
Trial: 14761073
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8‐12 mg once a day)
Trial: 14761073
Drug: Dihydropyridine calcium-channel
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium-channel blockers (DCCBs)
Trial: 10872643
Drug: tolcapone 50
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tolcapone 50 mg
Trial: 9591224
Drug: tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone 200 mg
Trial: 10872643
Drug: tolcapone 400
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tolcapone 400 mg
Trial: 10872643
Drug: tolcapone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (various doses)
Trial: 1984381
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (2 mg, 4 mg, placebo)
Trial: 6138061
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of midazolam
Trial: 6138061
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of midazolam
Trial: 6138061
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of midazolam
Trial: 29863387
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of tiagabine/day
Trial: 29863387
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of tiagabine/day (placebo)
Trial: 22299805
Drug: Prize-based contingency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prize-based contingency management (CM) intervention contingent on submitting negative urine drug screens (UDS)
Trial: 19185539
Drug: Pregabalin (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (exact dosage and duration not specified)
Trial: 17397610
Drug: Sodium heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium heparin 100 IU (study 1)
Trial: 17397610
Drug: Sodium heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium heparin 500 IU (control 1)
Trial: 17397610
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (SS) (study 2)
Trial: 17397610
Drug: Sodium heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium heparin 100 IU (control 2)
Trial: 10519944
Drug: 20 microg
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg of MSP-1(19) vaccine
Trial: 10519944
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of MSP-1(19) vaccine
Trial: 10519944
Drug: Control vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccines (hepatitis B or Td)
Trial: 2209838
Drug: Early second
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early second surgery after three cycles of cis-platinum-based chemotherapy (median of 14 weeks from initial laparotomy)
Trial: 7202896
Drug: metoprolol up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol up to 200 mg bid
Trial: 7202896
Drug: methyldopa up
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methyldopa up to 500 mg bid
Trial: 31740343
Drug: Ibandronate (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (150 mg/month)
Trial: 31740343
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D (daily)
Trial: 31740343
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (226 healthy premenopausal women receiving no treatments)
Trial: 27611235
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy-Enhanced (CBT-E)
Trial: 27611235
Drug: Integrative Cognitive-Affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Cognitive-Affective Therapy for BN (ICAT-BN)
Trial: 23565841
Drug: High-flavanol chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol chocolate (40g dose)
Trial: 23565841
Drug: Low-flavanol chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol chocolate (40g dose)
Trial: 23565841
Drug: High-flavanol chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol chocolate (20g daily intake for 12 weeks)
Trial: 23565841
Drug: Low-flavanol chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol chocolate (20g daily intake for 12 weeks)
Trial: 19208728
Drug: Somatostatin analogs
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analogs (SSA) treatment
Trial: 15494100
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E(2)V + 5 mg MPA
Trial: 15494100
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E(2)V + 2.5 mg MPA
Trial: 11806199
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (intravenous and supravenous)
Trial: 10193280
Drug: i.v. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketamine 10 mg i.v. bolus followed by 10 mg h‐1 infusion for 48 h
Trial: 8164327
Drug: PGE1 infusion
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 infusion at a rate of 30 ng.kg‐1 x min‐1 during surgery and 10‐30 ng.kg‐1 x min‐1 after surgery
Trial: 8164327
Drug: No PGE1
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No PGE1 infusion (control group)
Trial: 3284285
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy with mechanical ventilation (Group B)
Trial: 3284285
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy only (Group A)
Trial: 24282495
Drug: Joint Crisis
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint Crisis Plans (JCP) plus treatment as usual (TAU)
Trial: 21955538
Drug: Stroke volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke volume guided intra‐operative fluid management using LiDCOplus with maintenance fluid and 250 ml colloid boluses to achieve sustained 10% increases in stroke volume
Trial: 21955538
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration at the responsible (blinded) anaesthetist's discretion
Trial: 16534549
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day) continued for 6 weeks in group A
Trial: 16534549
Drug: Atorvastatin withdrawn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin withdrawn in group B
Trial: 16534549
Drug: Atorvastatin started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin started in groups C and D for 6 weeks
Trial: 16534549
Drug: Atorvastatin withdrawn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin withdrawn in group C after 6 weeks
Trial: 16534549
Drug: Atorvastatin continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin continued in group D after 6 weeks
Trial: 14559927
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times daily for 21 days
Trial: 10468218
Drug: L-DOPA treatment
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA treatment in PD patients
Trial: 25853905
Drug: 2-mg intraventricular
RxNorm normalized name: cerliponase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg intraventricular TPA every 12 hours
Trial: 24012128
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic treatment (group 1)
Trial: 24012128
Drug: Local antibiotic
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antibiotic treatment (group 2)
Trial: 21835135
Drug: Mepolizumab (0.55,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (0.55, 2.5, or 10 mg/kg) administered every 4 weeks for a total of 3 infusions
Trial: 17942818
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg IV
Trial: 17942818
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg IV (subgroup with migraine lasting longer than 72 hours)
Trial: 9506650
Drug: Milrinone lactate
RxNorm normalized name: milrinone lactate
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone lactate (50 microg/kg loading dose, then 0.5 microg/kg/min infusion)
Trial: 9506650
Drug: Milrinone lactate
RxNorm normalized name: milrinone lactate
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone lactate (after discontinuation of infusion)
Trial: 9506650
Drug: Milrinone lactate
RxNorm normalized name: milrinone lactate
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone lactate (during infusion)
Trial: 7635035
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human growth hormone (GH)
Trial: 3051628
Drug: Orchiectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiectomy plus combined hormone and chemotherapy (ethinylestradiol sulfonate plus vincristine/vinblastine, cyclophosphamide, methotrexate)
Trial: 3051628
Drug: Orchiectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiectomy plus antigonadotropic therapy alone (ethinylestradiol sulfonate)
Trial: 3051628
Drug: Orchiectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiectomy plus chemotherapy (vincristine/vinblastine, cyclophosphamide, methotrexate)
Trial: 15159134
Drug: Valerian extract
RxNorm normalized name: valerian extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian extract (600, 1200, and 1800 mg)
Trial: 9222733
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily in the morning
Trial: 9222733
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily in the evening
Trial: 28725977
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (60,000 IU orally, weekly for 4 weeks) and calcium supplements (500 to 1,000 mg/day for 3 months)
Trial: 23279924
Drug: Past 30‐day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past 30‐day daily average number of cigarettes smoked
Trial: 21991566
Drug: Post-operative treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative treatment with FPANS 100 μg q.i.d.
Trial: 21991566
Drug: Not treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not treated post-operatively with topical glucocorticoids
Trial: 17192770
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifampin (intravenous 30-min infusion)
Trial: 2737307
Drug: High-dose single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose single agent cisplatinum (19 patients)
Trial: 30646391
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg THC (smoked)
Trial: 30646391
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg THC (vaporized)
Trial: 30646391
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg THC (smoked)
Trial: 30646391
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg THC (vaporized)
Trial: 27500873
Drug: Pregabalin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (up to 600 mg a day for six days)
Trial: 24812898
Drug: Chinese medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medical enema for brain resuscitation, relieving rigidity of muscles and activating collaterals for 14 days, alongside comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Trial: 24812898
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Trial: 23176129
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of calcium carbonate combined with 400 IU of vitamin D(3)
Trial: 12544314
Drug: Terazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (1 to 5 mg daily for 14 weeks)
Trial: 10817352
Drug: Neoadjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoendocrine therapy followed by surgery
Trial: 10817352
Drug: Adjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoendocrine treatment after primary surgery
Trial: 9862047
Drug: Neoadjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoendocrine therapy
Trial: 6825540
Drug: Granulated pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulated pancreatic enzyme preparation (Pankreon)
Trial: 7990068
Drug: Psychological preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological preparation
Trial: 31340899
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic preparation)
Trial: 30134990
Drug: Parenting intervention
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenting intervention providing training in dialogic book-sharing, conducted weekly for 7 weeks.